IDYA darovasertib NDA nearing completion amid FDA feedback
IDEAYA Bio (IDYA) says a final NDA submission for darovasertib is imminent, with positive FDA feedback potentially enabling an all-comers label. Clinical and pipeline updates are slated for ESMO.
This is a real-time flash headline. A verified provider body is not available, so SquawkNews does not present it as a full article.